BERLIN and SEATTLE, May 9, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a cancer molecular diagnostics company developing products based on DNA methylation, has entered into an R&D collaboration with Myriad Genetics, Inc. (Nasdaq:MYGN) to identify and analyze DNA methylation biomarkers that may predict patients' response to an undisclosed marketed oncology drug.
